The present disclosure relates generally to the field of medical
oncology and, in particular, to methods and kits for identifying and treating neuroendocrine carcinomas, such as
small cell neuroendocrine (SCN) tumors. Certain aspects of the present disclosure can include methods of diagnosing a patient with a neuroendocrine
carcinoma, methods of determining a
survival prognosis in a patient diagnosed with a neuroendocrine
carcinoma, compositions that effectively inhibits or decreases an expression level of a
hepatocyte cell adhesion molecule 2 (HEPACAM2) biomarker
in vivo or
ex vivo, and methods of treating a patient having, or suspected of having, a neuroendocrine
carcinoma.